Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB : NSDQ)

• Company Description    Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel. Number of Employees: 20

• Price / Volume Information    Yesterday's Closing Price: $3.05 Daily Weekly Monthly 20 Day Moving Average: 33,460 shares Shares Outstanding: 11.40 (millions) Market Capitalization: $34.78 (millions) Beta: 1.17 52 Week High: $27.92 52 Week Low: $2.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.60% -2.68% 12 Week -22.00% -14.24% Year To Date -55.80% -45.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL KIRYAT ATIDIM BUILDING 7 - TEL AVIV,L3 6158002 ISR ph: 972-77-331-0156 fax: - arr@lifesciadvisors.com http://www.anchiano.com

• General Corporate Information    Officers Dale Pfost - Chief Executive Officer and Chairman Donald Marvin - Chief Financial Officer; Executive Vice President Adi Mor - Director Nissim Darvish - Director Joel Maryles - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 16385C104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 11.40 Most Recent Split Date: 3.00 (0.06:1) Beta: 1.17 Market Capitalization: $34.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.61 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -100.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -25.18 12/31/21 - -19.95 09/30/21 - -19.22 ROA 03/31/22 - -24.13 12/31/21 - -19.02 09/30/21 - -18.21 Current Ratio 03/31/22 - 16.87 12/31/21 - 23.66 09/30/21 - 40.39 Quick Ratio 03/31/22 - 16.87 12/31/21 - 23.66 09/30/21 - 40.39 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.02 12/31/21 - 5.39 09/30/21 - 5.75 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©